146 related articles for article (PubMed ID: 9527797)
21. Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
Lee Y; Park Y; Kim MS; Yong D; Jeong SH; Lee K; Chong Y
Antimicrob Agents Chemother; 2010 Sep; 54(9):3993-7. PubMed ID: 20585132
[TBL] [Abstract][Full Text] [Related]
22. Comparison of in vitro activities of DU-6859a and other fluoroquinolones against Japanese isolates of anaerobic bacteria.
Kato N; Kato H; Tanaka-Bando K; Watanabe K; Ueno K
Clin Infect Dis; 1996 Dec; 23 Suppl 1():S31-5. PubMed ID: 8953104
[TBL] [Abstract][Full Text] [Related]
23. [In vitro antibacterial activity of lomefloxacin, a new fluoroquinolone, against hospital strains. Results of a multicenter study].
Soussy CJ; Le Van Thoi J; Morel C; Acar JF; Thabaut A; Fleurette J; Vallée E; Dabernat H; Chanal M; Drugeon H
Pathol Biol (Paris); 1990 May; 38(5):390-6. PubMed ID: 2195448
[TBL] [Abstract][Full Text] [Related]
24. In vitro activity of Bay Y3118 against anaerobic bacteria.
Wexler HM; Molitoris E; Finegold SM
Antimicrob Agents Chemother; 1993 Nov; 37(11):2509-13. PubMed ID: 8285647
[TBL] [Abstract][Full Text] [Related]
25. In vitro activities of a new des-fluoro(6) quinolone, garenoxacin, against clinical anaerobic bacteria.
Liebetrau A; Rodloff AC; Behra-Miellet J; Dubreuil L
Antimicrob Agents Chemother; 2003 Nov; 47(11):3667-71. PubMed ID: 14576144
[TBL] [Abstract][Full Text] [Related]
26. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
Barry AL; Fuchs PC
J Chemother; 1997 Feb; 9(1):9-16. PubMed ID: 9106012
[TBL] [Abstract][Full Text] [Related]
27. In vitro activity of Bulgarian propolis against 94 clinical isolates of anaerobic bacteria.
Boyanova L; Kolarov R; Gergova G; Mitov I
Anaerobe; 2006 Aug; 12(4):173-7. PubMed ID: 16919977
[TBL] [Abstract][Full Text] [Related]
28. In vitro activity of the new fluoroquinolone CP-99,219.
Neu HC; Chin NX
Antimicrob Agents Chemother; 1994 Nov; 38(11):2615-22. PubMed ID: 7872757
[TBL] [Abstract][Full Text] [Related]
29. In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.
Barry AL; Fuchs PC
Antimicrob Agents Chemother; 1991 May; 35(5):955-60. PubMed ID: 1906696
[TBL] [Abstract][Full Text] [Related]
30. Review of the in vitro activity of gemifloxacin against gram-positive and gram-negative anaerobic pathogens.
Goldstein EJ
J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():55-65. PubMed ID: 10824034
[TBL] [Abstract][Full Text] [Related]
31. In-vitro activity of clinafloxacin (CI-960) and PD 131628-2 against anaerobic bacteria.
Wexler HM; Molitoris E; Reeves D; Finegold SM
J Antimicrob Chemother; 1994 Oct; 34(4):579-84. PubMed ID: 7868409
[TBL] [Abstract][Full Text] [Related]
32. [In vitro activity of trovafloxacin (CP-99,219) against 434 bacterial strains: comparative study with other fluoroquinolones].
Tali-Maamar H; Tebbal S; Rahal K
Arch Inst Pasteur Alger; 1998; 62():52-61. PubMed ID: 11256319
[TBL] [Abstract][Full Text] [Related]
33. [Pharmacokinetics of trovafloxacin: its clinical significance].
Clara LO; Biglia MA
Medicina (B Aires); 1999; 59 Suppl 1():17-22. PubMed ID: 10436550
[TBL] [Abstract][Full Text] [Related]
34. Impact of the fluoroquinolones on gastrointestinal flora.
Korten V; Murray BE
Drugs; 1993; 45 Suppl 3():125-33. PubMed ID: 7689443
[TBL] [Abstract][Full Text] [Related]
35. Comparative in vitro activity of meropenem versus other extended-spectrum antimicrobials against randomly chosen and selected resistant clinical isolates tested in 26 North American centers.
Pitkin DH; Sheikh W; Nadler HL
Clin Infect Dis; 1997 Feb; 24 Suppl 2():S238-48. PubMed ID: 9126699
[TBL] [Abstract][Full Text] [Related]
36. Comparative activity of the new fluoroquinolone rufloxacin (MF 934) against clinical isolates of gram-negative and gram-positive bacteria.
Qadri SM; Ueno Y; Postle G; Tullo D; San Pedro J
Eur J Clin Microbiol Infect Dis; 1993 May; 12(5):372-7. PubMed ID: 8394816
[TBL] [Abstract][Full Text] [Related]
37. In-vitro activity of temafloxacin against anaerobic bacteria: a comparative study.
Finegold SM; Molitoris E; Reeves D; Wexler HM
J Antimicrob Chemother; 1991 Dec; 28 Suppl C():25-30. PubMed ID: 1664827
[TBL] [Abstract][Full Text] [Related]
38. The chemistry and biological profile of trovafloxacin.
Brighty KE; Gootz TD
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():1-14. PubMed ID: 9222064
[TBL] [Abstract][Full Text] [Related]
39. In-vitro comparison of DU-6859a, a novel fluoroquinolone, with other quinolones and oral cephalosporins tested against 5086 recent clinical isolates.
Marshall SA; Jones RN; Murray PR; Washington JA; Allen SD; Gerlach EH; Erwin ME
J Antimicrob Chemother; 1993 Dec; 32(6):877-84. PubMed ID: 8144428
[No Abstract] [Full Text] [Related]
40. Increased activity of a new chlorofluoroquinolone, BAY y 3118, compared with activities of ciprofloxacin, sparfloxacin, and other antimicrobial agents against anaerobic bacteria.
Aldridge KE
Antimicrob Agents Chemother; 1994 Jul; 38(7):1671-4. PubMed ID: 7979307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
